Viral Genetics Inc. Submits Pre-IND Document for Lyme Disease Drug Candidate to FDA

Published: Mar 07, 2012

SAN MARINO, Calif.--(BUSINESS WIRE)--Viral Genetics (Pinksheets: VRAL) announced today that it has submitted a pre-IND briefing document to the US Food and Drug Administration (FDA) for its Lyme Disease drug candidate, VGV-L, marking important milestones for both the Company and its supporters in the Lyme community.

Back to news